Mikael Dolsten at #JPM24 (Brian Benton Photography)
April 2, 2025 08:00 AM EDT
People
AI

Ex­clu­sive: Mikael Dol­sten shares his post-Pfiz­er plans, in­clud­ing ad­vis­ing an AI uni­corn with phar­ma dreams

Andrew Dunn

Senior Biopharma Correspondent

Can AI make an avatar of Mikael Dol­sten? The for­mer chief sci­en­tif­ic of­fi­cer of Pfiz­er will try to find out now that he’s start­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Cor­rect­ed: Trump's broad tar­iffs could mark a 'dou­ble wham­my' for phar­ma af­ter FDA cuts

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

Roche says Ocre­vus failed Phase 3 study; Sanofi li­cens­es au­toim­mune as­set from Nurix

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times